Marginal Orbicularis Oris Hyperactivity (MOOH): An Exploratory Case Series of Inversion-Dominant Upper Lip Dynamics Following Intraoral Botulinum Toxin Type A.
Abstract
Excessive gingival display (EGD) is most commonly attributed to vertical upper lip elevation, short lip length, or dentoalveolar disproportion. However, some patients exhibit gingival or mucosal visibility during smiling despite minimal vertical upper lip displacement, suggesting the presence of alternative dynamic patterns. This exploratory case series examined an inversion-dominant smile presentation and its documented modulation in association with conservative intraoral chemodenervation directed toward the marginal region of the orbicularis oris. Ninety-four patients with dynamic inversion during smiling were assessed using a qualitative rating aid (Armenti Inversion Scale, AIS) and a quantitative composite proportional measure of vermilion loss (ΔLv%). All patients received low-dose intraoral Onabotulinum toxin A (4-6 U) as part of routine aesthetic care. At Day 15 follow-up, a shift toward lower inversion grades was observed across the cohort, with a large proportion of patients showing minimal residual inversion. Quantitative ΔLv% values showed proportional changes that were directionally consistent with shifts in AIS grade. The functional alterations were mild, transient, and self-resolving. Preliminary inter-rater agreement for AIS and measurement repeatability for ΔLv% suggested acceptable internal consistency for exploratory reporting tools. These findings suggest that inward vermilion inversion may represent a potentially distinct dynamic contributor to gingival or mucosal exposure in selected individuals, and that conservative marginal chemodenervation was associated with transient modulation of this pattern with generally preserved oral competence. AIS and ΔLv% are preliminary documentation tools. Further studies incorporating objective neuromuscular assessment, three-dimensional imaging, and comparative designs are required to refine phenotypic characterization.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | upper lip
|
scispacy | 1 | ||
| 해부 | mucosal
|
scispacy | 1 | ||
| 해부 | intraoral
|
scispacy | 1 | ||
| 해부 | oral
|
scispacy | 1 | ||
| 해부 | ΔLv%
|
scispacy | 1 | ||
| 해부 | neuromuscular
|
scispacy | 1 | ||
| 합병증 | lip
|
scispacy | 1 | ||
| 약물 | Armenti
|
scispacy | 1 | ||
| 약물 | low-dose
|
C1708745
Low-Dose Treatment
|
scispacy | 1 | |
| 약물 | Onabotulinum toxin A
|
C4743433
onabotulinum toxin A
|
scispacy | 1 | |
| 약물 | MOOH
|
scispacy | 1 | ||
| 질환 | Hyperactivity
|
C0424295
Hyperactive behavior
|
scispacy | 1 | |
| 질환 | dentoalveolar disproportion
|
scispacy | 1 | ||
| 질환 | vermilion loss
|
scispacy | 1 | ||
| 질환 | Marginal Orbicularis Oris
|
scispacy | 1 | ||
| 질환 | Case
|
scispacy | 1 | ||
| 질환 | EGD
→ Excessive gingival display
|
scispacy | 1 | ||
| 질환 | orbicularis oris
|
scispacy | 1 | ||
| 기타 | Botulinum Toxin Type A.
|
scispacy | 1 | ||
| 기타 | dentoalveolar
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 |
MeSH Terms
Humans; Botulinum Toxins, Type A; Female; Lip; Male; Adult; Smiling; Middle Aged; Facial Muscles; Neuromuscular Agents; Young Adult
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.